Jocelyn Staunton

761 total citations
17 papers, 260 citations indexed

About

Jocelyn Staunton is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jocelyn Staunton has authored 17 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Jocelyn Staunton's work include PI3K/AKT/mTOR signaling in cancer (6 papers), RNA modifications and cancer (3 papers) and Advanced Breast Cancer Therapies (2 papers). Jocelyn Staunton is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), RNA modifications and cancer (3 papers) and Advanced Breast Cancer Therapies (2 papers). Jocelyn Staunton collaborates with scholars based in United States. Jocelyn Staunton's co-authors include Michael H. Dickinson, Fritz‐Olaf Lehmann, Qingxiang Liu, Jinlong Chen, Juan C. Jaén, Nigel P.C. Walker, Michelle Lindström, Yang Li, R. Marc Learned and Gary Lee and has published in prestigious journals such as Blood, Journal of Molecular Biology and Cancer Research.

In The Last Decade

Jocelyn Staunton

16 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jocelyn Staunton United States 6 179 36 36 31 29 17 260
Shufen Chen United States 11 225 1.3× 11 0.3× 25 0.7× 32 1.0× 16 0.6× 28 345
Pengbo Yao China 12 260 1.5× 32 0.9× 13 0.4× 37 1.2× 24 0.8× 17 450
Kazuo Watanabe Japan 10 157 0.9× 11 0.3× 28 0.8× 30 1.0× 17 0.6× 25 322
M. Irina Stefana United Kingdom 8 138 0.8× 23 0.6× 16 0.4× 12 0.4× 40 1.4× 14 290
Runu Dey United States 12 425 2.4× 14 0.4× 19 0.5× 16 0.5× 26 0.9× 16 532
Brian Coblitz United States 9 438 2.4× 48 1.3× 16 0.4× 19 0.6× 9 0.3× 9 489
Renato Colaço United Kingdom 8 298 1.7× 17 0.5× 7 0.2× 17 0.5× 42 1.4× 10 589
Francisco Martı́nez-Azorı́n Spain 14 320 1.8× 42 1.2× 10 0.3× 25 0.8× 21 0.7× 36 426
Geoffray Monteuuis Finland 8 295 1.6× 14 0.4× 9 0.3× 12 0.4× 26 0.9× 14 380
Nelly Godefroy France 10 169 0.9× 16 0.4× 18 0.5× 42 1.4× 42 1.4× 18 296

Countries citing papers authored by Jocelyn Staunton

Since Specialization
Citations

This map shows the geographic impact of Jocelyn Staunton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyn Staunton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyn Staunton more than expected).

Fields of papers citing papers by Jocelyn Staunton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyn Staunton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyn Staunton. The network helps show where Jocelyn Staunton may publish in the future.

Co-authorship network of co-authors of Jocelyn Staunton

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyn Staunton. A scholar is included among the top collaborators of Jocelyn Staunton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyn Staunton. Jocelyn Staunton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wang, Yan, Allison W. Roberts, Philamer Calses, et al.. (2024). Abstract 5949: The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC. Cancer Research. 84(6_Supplement). 5949–5949. 1 indexed citations
2.
Wang, Yan, Richard M. Neve, Jocelyn Staunton, & Kevin R. Webster. (2024). Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance. Cancer Research. 84(6_Supplement). 5948–5948. 3 indexed citations
3.
Gerson‐Gurwitz, Adina, Nathan P. Young, Vikas Goel, et al.. (2021). Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors. Frontiers in Oncology. 11. 766298–766298. 22 indexed citations
4.
Thompson, Peggy A., Nathan P. Young, Craig R. Stumpf, et al.. (2019). Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers. Molecular Cancer Therapeutics. 18(12_Supplement). B133–B133. 3 indexed citations
5.
6.
Sharma, Rajesh, Vikas Goel, Jocelyn Staunton, et al.. (2018). Abstract 5546: eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response. Cancer Research. 78(13_Supplement). 5546–5546. 2 indexed citations
7.
Webster, Kevin R., Vikas Goel, Jocelyn Staunton, et al.. (2017). Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade. Cancer Research. 77(6_Supplement). PR11–PR11. 3 indexed citations
8.
Webster, Kevin R., Vikas Goel, Jocelyn Staunton, et al.. (2017). Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity. Cancer Research. 77(13_Supplement). 596–596. 3 indexed citations
9.
10.
Wang, Shunyou, Katti Jessen, Linda Kessler, et al.. (2012). Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer. Cancer Research. 72(8_Supplement). 3753–3753. 4 indexed citations
11.
Jessen, Katti, Linda Kessler, Jeff Kucharski, et al.. (2011). Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.. Molecular Cancer Therapeutics. 10(11_Supplement). A171–A171. 14 indexed citations
12.
Wang, Shunyou, Katti Jessen, Linda Kessler, et al.. (2011). Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer. Cancer Research. 71(8_Supplement). 4486–4486. 1 indexed citations
13.
Jessen, Katayoun A., Linda Kessler, Jeff Kucharski, et al.. (2011). Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer. Cancer Research. 71(8_Supplement). 4501–4501. 5 indexed citations
14.
Jessen, Katayoun A., Shunyou Wang, Xin Guo, et al.. (2010). Abstract 1668: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer. Cancer Research. 70(8_Supplement). 1668–1668. 1 indexed citations
15.
Jessen, Katayoun A., Shunyou Wang, Linda Kessler, et al.. (2009). Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity. Molecular Cancer Therapeutics. 8(12_Supplement). B148–B148. 20 indexed citations
16.
Motani, Alykhan, Zhulun Wang, Jennifer Weiszmann, et al.. (2009). INT131: A Selective Modulator of PPARγ. Journal of Molecular Biology. 386(5). 1301–1311. 98 indexed citations
17.
Lehmann, Fritz‐Olaf, Michael H. Dickinson, & Jocelyn Staunton. (2000). The Scaling of Carbon Dioxide Release and Respiratory Water Loss in Flying Fruit Flies (Drosophila Spp.). Journal of Experimental Biology. 203(10). 1613–1624. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shufen Chen Breakdown of academic impact, for papers by Pengbo Yao Breakdown of academic impact, for papers by Kazuo Watanabe Breakdown of academic impact, for papers by M. Irina Stefana Breakdown of academic impact, for papers by Runu Dey Breakdown of academic impact, for papers by Brian Coblitz Breakdown of academic impact, for papers by Renato Colaço Breakdown of academic impact, for papers by Francisco Martı́nez-Azorı́n Breakdown of academic impact, for papers by Geoffray Monteuuis Breakdown of academic impact, for papers by Nelly Godefroy
Rankless by CCL
2026